Effect of Sulfonylurea Treatment on In Vivo Insulin Secretion and Action in Patients With Non-insulin-dependent Diabetes Mellitus
The DOI matches its Crossref record.
Abstract
The effect of glipizide treatment on diabetic control and on in vivo insulin secretion and action was studied in 20 patients with non-insulin-dependent diabetes mellitus (NIDDM). Patients were examined before and after a minimum of 3 mo treatment. Mean (± SEM) fasting plasma glucose level fell from 264 ± 12 mg/dl to 172 ± 10 mg/dl (P < 0.001) after glipizide treatment, and this was associated with a fall in total plasma glucose response to a test meal of approximately 35﹪. Mean (±SEM) fasting plasma insulin levels increased slightly from 15 ± 2 μU/ml to 18 ± 2 μU/ml following sulfonylurea treatment, and the total plasma insulin response to the test meal increased by 63﹪. However, there was no correlation (r = −0.20) between the increase in plasma insulin response and the fall in plasma glucose levels that occurred as the result of sulfonylurea therapy. Glipizide treatment also led to enhanced in vivo insulin action, whether measured by the insulin clamp technique (P < 0.001) or the insulin suppression test (P < 0.02). Furthermore, in this instance there was a significant correlation (r = 0.69, P < 0.001) between the enhanced insulin action and the improvement on diabetes control. Thus, chronic therapy with glipizide, a new sulfonylurea agent, led to increased in vivo insulin secretion and insulin action. These results lend direct support to the assumption that sulfonylurea compounds have a substantial extrapancreatic effect on glucose homeostasis, and suggest that this effect contributes to the therapeutic efficacy of these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
Insulin action and insulin resistance in human skeletal muscle
Zierath, J. R., Krook, A., & Wallberg-Henriksson, H. (2000) · Diabetologia · doi:10.1007/s001250051457 · Cited by 367
“In Type II diabetic patients, restoration of euglycaemia after weight loss [111, 112], sulphonylurea treatment [113, 114] or insulin therapy [115, 116] enhances insulin sensitivity in adipocytes and skeletal muscle.”
BackgroundHOLLENBECK, C., & REAVEN, G. M. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-6-1169 · Cited by 307
Self-citationInsulin release and peripheral sensitivity at the oral glucose tolerance test
Cederholm, J., & Wibell, L. (1990) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(90)90040-z · Cited by 264
Pagano, G., Cavallo-Perin, P., Cassader, M., Bruno, A., Ozzello, A., Masciola, P., Dall'omo, A. M., & Imbimbo, B. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111141 · Cited by 259
Metadata
- Authors
- Greenfield, M. S., Doberne, L., Rosenthal, M., Schulz, B., Widstrom, A., & Reaven, G. M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1982-04-01
- Volume
- 31
- Issue
- 4
- Pages
- 307-312
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2108544807
- Cited by
- 117
- References
- 0
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Sulfonylurea Treatment on In Vivo Insulin Secretion and Action in Patients With Non-insulin-dependent Diabetes Mellitus. https://app.cochat.ai/papers/10.2337/diab.31.4.307
- The paper
- Greenfield, M. S., Doberne, L., Rosenthal, M., Schulz, B., Widstrom, A., & Reaven, G. M. (1982). Effect of Sulfonylurea Treatment on In Vivo Insulin Secretion and Action in Patients With Non-insulin-dependent Diabetes Mellitus. Diabetes. https://doi.org/10.2337/diab.31.4.307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.